英国国家卫生与护理卓越研究所（NICE）已推荐抗癌药物恩赫图用于英格兰国民医疗制度（NHS）常规治疗，约1000名患有HER2低表达晚期乳腺癌的女性从本周四起可获得该药物1。这一决定源于NHS与制药商阿斯利康和第一三共成功完成的价格谈判1。
NICE曾于2024年7月因成本考虑拒绝了这款药物，但在获得更高的年度治疗预算上限支持后改变了立场1。根据最新协议，该药物的年度治疗预算上限从3万英镑提升至3.5万英镑1。临床试验数据显示，恩赫图能够显著改善患者生存情况，使无进展生存期中位数从5.1个月延长至9.9个月，总体生存期从16.8个月延长至23.4个月，增加了6.6个月1。
恩赫图已于2023年12月在苏格兰上市，并已在27个欧洲国家作为治疗药物提供1。威尔士和北爱尔兰政府可能效仿实施这一建议1。
The UK's National Institute for Health and Care Excellence (NICE) has recommended that the drug Enhertu be made available through the National Health Service for approximately 1,000 women annually with HER2-low advanced breast cancer 1. This decision follows successful price negotiations between NHS England, pharmaceutical manufacturers AstraZeneca and Daiichi Sankyo, with the treatment becoming accessible from this Thursday 1.
NICE had previously rejected the medication in July 2024 on cost grounds, but reversed its position after securing an increased annual treatment budget threshold, raised from £30,000 to £35,000 per patient 1. Clinical trial evidence demonstrates that Enhertu extends median progression-free survival from 5.1 months to 9.9 months and increases median overall survival by 6.6 months, from 16.8 months to 23.4 months 1. The drug has already been available in Scotland since December 2023 and is offered across 27 European countries 1. Welsh and Northern Irish governments may follow suit with their own implementation of this recommendation 1.
评论
还没有评论，欢迎留下第一条。